I am not sure why some are crowing about insider trading. The announcement did state:
The presentation entitled “Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N- glycolylneuraminic acid-specific lectin SubB2M”, was delivered by Dr Lucy Shewell from Griffith University’s Institute for Glycomics at the ANZGOG Conference. Dr Shewell reported that serum from 47 patients with all stages of ovarian cancer had significantly elevated mean levels of Neu5Gc glycans compared to 22 cancer-free control individuals.
Now if I was sitting in the audience, I would probably want to buy some shares in BD1. So when was the presentation delivered?
